Group 1 - Oneok Inc. reported $7.89 billion in revenue for Q2 2025, a year-over-year increase of 61.2%, with EPS of $1.34 compared to $1.33 a year ago [1] - The reported revenue was below the Zacks Consensus Estimate of $8.56 billion, resulting in a surprise of -7.91%, while the EPS met the consensus estimate [1] - Over the past month, Oneok's shares returned -6.7%, contrasting with the Zacks S&P 500 composite's +1.9% change, and the stock holds a Zacks Rank 3 (Hold) [3] Group 2 - Raw feed throughput for Natural Gas Liquids was 1,527.00 MBBL/d, below the average estimate of 1,702.67 MBBL/d [4] - Revenues from Natural Gas Gathering and Processing reached $1.85 billion, significantly exceeding the average estimate of $1.37 billion, representing a year-over-year change of +118.4% [4] - Revenues from Natural Gas Pipelines were $405 million, surpassing the estimated $161.26 million, with a year-over-year increase of +148.5% [4] - Revenues from Refined Products & Crude totaled $2.91 billion, well above the average estimate of $992.77 million [4] - Revenues from Natural Gas Liquids amounted to $3.87 billion, exceeding the average estimate of $3.06 billion, with a year-over-year change of +9.7% [4] - Adjusted EBITDA for Natural Gas Liquids was $673 million, slightly below the estimated $725 million [4] - Adjusted EBITDA for Refined Products & Crude was $557 million, slightly above the average estimate of $549.48 million [4] - Adjusted EBITDA for Natural Gas Pipelines reached $188 million, exceeding the average estimate of $145.59 million [4] - Adjusted EBITDA for Natural Gas Gathering and Processing was $540 million, in line with the average estimate of $538.82 million [4]

Core Insights - ConocoPhillips reported revenue of $14.74 billion for the quarter ended June 2025, reflecting a 4.3% increase year-over-year, but fell short of the Zacks Consensus Estimate by 1.25% [1] - The company's EPS was $1.42, down from $1.98 in the same quarter last year, but exceeded the consensus estimate of $1.36 by 4.41% [1] Financial Performance - Total production per day was 2,391 million barrels of oil equivalent, surpassing the eight-analyst average estimate of 2,362.71 million barrels [4] - Natural gas production was 4,005 million cubic feet per day, exceeding the seven-analyst average estimate of 3,985.42 million cubic feet [4] - Crude oil production was 1,155 million barrels per day, slightly above the six-analyst average estimate of 1,153.05 million barrels [4] - Sales and other operating revenues were reported at $14 billion, lower than the five-analyst average estimate of $14.68 billion, but showed a year-over-year increase of 2.8% [4] - Equity in earnings of affiliates was $315 million, exceeding the four-analyst average estimate of $259.2 million, but represented a year-over-year decline of 21.8% [4] Market Performance - ConocoPhillips shares returned -1.5% over the past month, while the Zacks S&P 500 composite increased by 1.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Aflac reported revenue of $4.54 billion for the quarter ended June 2025, reflecting an 11.7% decrease year-over-year, but exceeded the Zacks Consensus Estimate by 2.3% [1] - Earnings per share (EPS) for the quarter was $1.78, down from $1.83 in the same quarter last year, surpassing the consensus EPS estimate of $1.71 by 4.09% [1] Financial Performance Metrics - Aflac Japan's Total Benefit/Premium was 66.5%, exceeding the average estimate of 65.3% [4] - Aflac U.S. Total Adjusted Expenses/Total Adjusted Revenue was 36.3%, better than the average estimate of 38.1% [4] - Aflac U.S. Total Adjusted Revenues were reported at $1.73 billion, slightly below the estimated $1.74 billion, but showed a year-over-year increase of 2.6% [4] - Aflac Japan's Total Adjusted Revenues were $2.47 billion, surpassing the estimate of $2.38 billion, with a year-over-year change of 1% [4] - Total net earned premiums for Aflac U.S. were $1.5 billion, compared to the estimate of $1.52 billion, reflecting a 3.4% increase year-over-year [4] - Other income for Aflac Japan was reported at $12 million, significantly higher than the estimated $6.67 million, marking a 71.4% year-over-year increase [4] - Net investment income was $1.08 billion, slightly below the estimate of $907.26 million, showing a 1.3% decrease year-over-year [4] - Total net earned premiums across the company were $3.47 billion, exceeding the estimate of $3.44 billion, with a year-over-year increase of 4.4% [4] - Corporate and other adjusted revenues were $336 million, surpassing the average estimate of $328.5 million, representing a 34.9% year-over-year change [4] Stock Performance - Aflac's shares have returned -4.2% over the past month, contrasting with a +1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Moderna reported revenue of $142 million for the quarter ended June 2025, a decrease of 41.1% year-over-year, with an EPS of -$2.13 compared to -$3.33 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $127.17 million by 11.66%, while the EPS also surpassed the consensus estimate of -$2.99 by 28.76% [1] Revenue Breakdown - Product sales in the United States were $88 million, significantly higher than the average estimate of $28.31 million, but represented a year-over-year decline of 45.7% [4] - Product sales in the Rest of the World reached $26 million, below the average estimate of $42.95 million, but showed an 18.2% increase year-over-year [4] - Net product sales totaled $114 million, exceeding the average estimate of $81.42 million, but reflected a 38% decrease compared to the previous year [4] - Other revenue amounted to $28 million, slightly above the average estimate of $25.13 million, but indicated a 50.9% decline year-over-year [4] - Grant revenue was reported at $5 million, compared to the average estimate of $6.16 million [4] - Licensing and royalty revenue was $2 million, significantly lower than the average estimate of $10.65 million [4] - Collaboration revenue reached $4 million, below the average estimate of $7.5 million [4] Stock Performance - Over the past month, Moderna's shares have returned -3.1%, contrasting with the Zacks S&P 500 composite's increase of 2.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Middlefield Banc Corp. (MBCN) reported a revenue of $20.52 million for the quarter ended June 2025, reflecting a year-over-year increase of 21.8% [1] - The earnings per share (EPS) for the same quarter was $0.76, up from $0.52 in the previous year [1] - The reported revenue exceeded the Zacks Consensus Estimate by 10.3%, while the EPS surprise was 33.33% above the consensus estimate [1] Financial Performance Metrics - The efficiency ratio was reported at 64.5%, better than the average estimate of 67.5% from two analysts [4] - The net interest margin stood at 3.9%, surpassing the average estimate of 3.7% [4] - Average interest-earning assets were $1.83 billion, slightly above the estimated $1.8 billion [4] - Total noninterest income was $3.08 million, significantly higher than the estimated $1.85 million [4] - Net interest income reached $17.44 million, exceeding the average estimate of $16.75 million [4] Stock Performance - Over the past month, shares of Middlefield Banc have returned +0.9%, compared to a +5.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Interparfums reported revenue of $338.82 million for Q1 2025, a year-over-year increase of 4.6% and a surprise of +0.47% over the Zacks Consensus Estimate of $337.22 million [1] - The EPS for the same period was $1.32, compared to $1.27 a year ago, with an EPS surprise of +16.81% against the consensus estimate of $1.13 [1] Revenue Performance by Region - North America: Net sales of $123 million, exceeding the average estimate of $119.03 million, with a year-over-year change of +13.8% [4] - Western Europe: Net sales of $86.20 million, above the average estimate of $74.28 million, reflecting a +1.3% year-over-year change [4] - Eastern Europe: Net sales of $25.60 million, surpassing the average estimate of $20.80 million, with a significant year-over-year increase of +46.3% [4] - Central and South America: Net sales of $31 million, slightly below the average estimate of $31.22 million, showing a year-over-year decline of -9.9% [4] - Middle East and Africa: Net sales of $22.70 million, below the average estimate of $29.97 million, with a year-over-year decrease of -16.2% [4] - Asia/Pacific: Net sales of $50.30 million, compared to the average estimate of $56.36 million, reflecting a -2.9% year-over-year change [4] - Europe: Total net sales of $247.80 million, exceeding the average estimate of $242.70 million, with a year-over-year increase of +7.3% [4] - United States: Net sales of $94.30 million, below the average estimate of $96.76 million, indicating a -1.5% year-over-year change [4] Stock Performance - Interparfums shares have returned +8.6% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]